SCB-313

DRUG5 trials

Sponsors

Clover Biopharmaceuticals AUS Pty, Sichuan Clover Biopharmaceuticals, Inc.

Conditions

Malignant AscitesMalignant Pleural EffusionMalignant Pleural EffusionsPeritoneal CarcinomatosisPeritoneal Malignancies

Phase 1

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies

CompletedNCT03443674

Clover Biopharmaceuticals AUS PtyPeritoneal Malignancies

Start: 2018-06-18End: 2021-08-26Updated: 2021-10-19

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions

CompletedNCT03869697

Clover Biopharmaceuticals AUS PtyMalignant Pleural Effusions

Start: 2019-11-20End: 2021-11-23Updated: 2022-02-02

A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis

TerminatedNCT04047771

Sichuan Clover Biopharmaceuticals, Inc.Peritoneal Carcinomatosis

Start: 2019-09-10End: 2022-05-05Updated: 2023-04-12

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites

CompletedNCT04051112

Sichuan Clover Biopharmaceuticals, Inc.Malignant Ascites

Start: 2019-09-28End: 2022-04-21Updated: 2022-05-06

A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion

CompletedNCT04123886

Sichuan Clover Biopharmaceuticals, Inc.Malignant Pleural Effusion

Start: 2020-01-08End: 2022-03-31Updated: 2022-05-06

Related Papers

Abstract 6180: First-in-human (FIH) phase I studies of SCB-313, a novel TNF-related apoptosis-inducing ligand TRAIL-Trimer™ fusion protein, for treatment of patients (pts) with malignant ascites (MA)

Cancer Research2022-06-153 citations